CA2046734A1 - Substituted pyrrolo-pyridines pharmaceuticals - Google Patents

Substituted pyrrolo-pyridines pharmaceuticals

Info

Publication number
CA2046734A1
CA2046734A1 CA002046734A CA2046734A CA2046734A1 CA 2046734 A1 CA2046734 A1 CA 2046734A1 CA 002046734 A CA002046734 A CA 002046734A CA 2046734 A CA2046734 A CA 2046734A CA 2046734 A1 CA2046734 A1 CA 2046734A1
Authority
CA
Canada
Prior art keywords
carbon atoms
formula
chain
straight
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002046734A
Other languages
French (fr)
Inventor
Walter Hubsch
Rolf Angerbauer
Peter Fey
Hilmar Bischoff
Joachim Bender
Delf Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of CA2046734A1 publication Critical patent/CA2046734A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Substituted pyrrolo-pyridines A b s t r a c t Substituted pyrrolo-pyridines can be prepared by reduc-tion of the corresponding ketones. They are useful active compounds for medicaments and can be employed, for example, for the treatment of hyperlipoproteinaemia, lipoproteinaemia and arteriosclerosis.

Description

20~6~

- The invention relates to substituted pyrrolo-pyridines, to intermediate compounds for their preparation, and to - their preparation and their use in medicaments.

It is known that lactone derivatives isolated from fungal cultures are inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase) tmevinolin, EP 22,478; US 4,231,938].

Phosphorus-containing HMG-CoA reductase inhibitors having antihypercholesterolaemic activity are additionally published in DE 3,817,298 A1.

New subs~ituted pyrrolo-pyridines of the general formula (I) RS ~
R4 ~ N ~ Rl (I) R

in which R1 - represents straight-chain or branched alkyl having up to 8 carbon atoms, or - represents cycloalkyl having 3 to 6 carbon atoms, R2 _ represents phenyl which is optionally monosub-stituted or disubstituted by identical or different substituents from the series comprising straight-~e A 27 777 - l -2~7~

chain or branched alkyl having up to 6 carbon atoms, trifluoromethyl, hydroxymethyl, phenoxy, benzyl, benzyloxy or halogen, R3 - represents hydrogen, - represents straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally sub-stituted by cyano, straight-chain or branched alkoxy having up to 6 carbon atoms, halogen, pyridyl, quinolinyl, furyl, thienyl, naphthyl or phenyl, each of which can in turn be substituted by halogen, cyano, nitro, or straight-chain or branched alkyl or alkoxy in each case having up to 6 carbon atoms, - represents straight-chain or branched alkenyl or alk~nyl in each case having up to 8 carbon atoms, lS or - represents cycloalkyl having 3 to 6 carbon atoms or phenyl, R4 and Rs are identical or different and - represent hydrogen,or - represent straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally sub-stituted by hydroxyl, halogen, cyano or alkoxy having up to 4 carbon atoms, X - represent~ a radical of the formula -A-B, in which Le A 27 777 - 2 -20'1~73~

- A - denotes a group of the formula -CH2-CH2- or -CH=CH-, B - denotes a group of the formula - CH -CH2-C-CH2-cooR7 or ~ O
OH OH
in which R6 _ denotes hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms and R7 - denotes hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which can be substituted by phenyl, or - denotes aryl having 6 to 10 carbon atoms or a cation, or - represents a radical of the formula Le A 27 777 - 3 -20~67~4 - oR8 in which D - denotes a radical of the formula -(CH2)t, -CH=CH-, -C.C- or -CH2-O-, in which the latter is bonded to the phosphorus atom via 0, R7 has the abovementioned meaning of R7, R8 _ denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms t - denotes the number 1 or 2, and their salts have been found.

If R7 forms an ester radical with the carboxyl group, a physiologically tolerable ester radical is preferably meant by this, which is easily hydrolyzed in vivo to give a free carboxyl group and a corresponding physiologically tolerable alcohol. These include, for example, alkyl esters (C~ to C6) and aralkyl esters (C7 to C10), prefer-ably (C,-C4)-alkyl esters and benzyl esters. Moreover, the following ester radicals may be mentioned: methyl esters, ethyl esters, propyl e~ter~ and benzyl esters.

Le A 27 777 - 4 -20~734 l If R7 represents a cation, a physiologically tolerable ¦ metal cation or ammonium cation is preferably meant.
/ - Preferred cations in this connection are alkali metal cations or alkaline earth metal cations such as, for example, sodium, potassium, magnesium or calcium cations, and also alumin~m or ammonium cations, as well as non-toxic substituted ammonium cations formed from amines such as (C1-C4)-dialkylamines, (C1-C4)-trialkylamines, procaine, dibenzylamine, N,N'-dibenzylethylenediamine, N-benzyl-~-phenylethylamine, N-methylmorpholine or N-ethylmorpholine, l-ephenamine, dihydroabietylamine, N,N'-bis-dihydroabietylethylenediamine, N-lower alkyl-piperidine and other amines which can be used for the formation of salts.

Ra can likewise represent one of the abovementioned physiologically tolerable metal cations or ammonium cations.

Surprisingly, the substituted pyrrolo-pyridines according to the invention show a superior inhibitory action on HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase).

Preferred compounds of the general formula (I) are those in which R1 - represents ~traight-chain or branched alkyl having up to 6 carbon atoms, or Le A 27 777 - 5 -20~67~

- represents cyclopropyl, cyclopentyl or cyclohexyl, R2 _ represents phenyl which is optionally substituted by straight-chain or branched alkyl having up to 4 carbon atoms, trifluoromethyl, fluorine, chlorine or bromine, R3 - represents hydrogen, - represents straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally sub-stituted by cyano, straight-chain or branched alkoxy having up to 4 carbon atoms, fluorine, chlorine, . bromine, pyridyl or phenyl, each of which can in turn be substituted by fluorine, chlorine, bromine cyano, nitro, straight-chain or branched alkyl or alkoxy in each case having up to 4 carbon atoms, - r2presents straight-chain or branched alkenyl or alkynyl in each case having up to 6 carbon atoms, or - represents cyclopropyl, cyclopentyl, cyclohexyl or phenyl, R4 and R5 represent hydrogen, X - represents a radical of the formula -A-B, in which A - denotes a group of the formula -CH2-CH2- or -CH=CH-, Le A 2? 77? - 6 -2~67~'~

- B - denotes a group of the formula -CH-CH2-C-CH2-CooR7 or R6 OH OH

in which R5 - denotes hydrogen and R7 - denotes hydrogen or straight-chain or branched alkyl having up to 8 carbon atoms.
or benzyl, or - denotes phenyl or a cation, and their salts.

Particularly preferred compounds of the general formula (I) are those in which R1 - represents straight-chain or branched alkyl having up to ~ carbon atoms or cyclopropyl, R2 _ represents phenyl which i~ optionally substituted by methyl, trifluoromethyl, fluorine or chlorine, Le A 27 777 - 7 -2 ~ 7 '.-.~ 4 R3 - represents hydrogen, - represents straight-chain or branched alkyl having - up to 6 carbon atoms, which is optionally sub-stituted by cyano, methoxy, fluorine, pyridyl or phenyl, - represents straight-chain or branched alkenyl or alky~yl in each case having up to 4 carbon atoms, or - represents cyclopentyl or cyclohexyl, R4 and R5 represent hydrogen, X - represents a radical of the formula -A-B, in which A - denotes a group of the formula -CH2-CH2- or -CH=CH-, B - denotes a group of the formula -CH-CH2-C-CH2-CooR7 Ho ¦ l l l or o OH OH

in which R6 _ denotes hydrogen and Le A 27 777 - 8 -20~6 ~34 - R7 - denotes hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or - benzyl, or - denotes a sodium, potassium, calcium, magnesium or ammonium ion, and their salts.

The substituted pyrrolo-pyridines of the general formula (I) according to the invention have several asymmetric carbon atoms and can therefore exist in various stereo-chemical forms. The invention relates both to the ;n-dividual isomers and to their mixtures. ..
.

Depending on the meaning of the radicals given under the substituent X, different stereoisomers result, which -is explained in more detail as exemplified by the radical lS -A-B as follows:

a) If the group -A- represents a group of the formula -CH=CH-, the compounds according to the invention can exist in two stereoisomeric forms which can have the E-configuration (II) or Z-configuration (III) of the doubIe bonds R5~ ( II ) E-form R4~N~R 1 Le A 27 777 - 9 -204~7~

.

RSJ~
R4'A~N ~ R1B 1III) Z-form in which Rl, R2, R3, R4, R5 and B have the abovementioned meaningS.

Preferred compounds of the general formula (I) are those which have the E-configuration (II).

b) If the radical -B represents a group of the formula - CH - CH2 - C - CH2 - CoOR7 OH OH

the compounds of the general formula (I) have at least two asymmetric carbon atoms, namely the two carbon atoms to which the hydroxyl groups are bonded. Depending on the relative position of these hydroxyl groups to one another, the compounds according to the invention can be present in the erythro-configuration (IV) or in the threo-configuration (V).

Le A 27 777 - 10 -- 20~6~3~

.

R5~b~A eH - CH2 - C - CH2 - CoOR7 R4~N~Rl OH OH Erythro-form (IV) R5 ~ A -CH-CH2-C-CH2-CooR7 Threo-form (V) R4~N ~Rl OH OH

In each case, two enantiomers, namely the 3R,5S-isomer or the 3S,SR-isomer (erythro-form) and the 3R,5R-isomer and the 3S,5S-isomer (threo-form) in turn exist both of the compounds in the erythro- and in the threo-configuration.

The isomers in the erythro-configuration are preferred in this case, particularly preferably the 3R,5S-isomer and the 3R,5S-3S,5R-racemate.

c) If the radical -B- represents a group of the formula R6~0 HO ¦
HX
the substituted pyrrolo-pyridines have at least two asym-metric carbon atomq, namely the carbon atom to which the hydroxyl group i8 bonded, and the carbon atom to which the radical of the formula Le A 27 777 - 11 -20~6~

. ' R2 R 5 ~.~A -R4--~N~R 1 R-~
is bonded. Depending on the position of the hydroxyl group to the free valency on the lactone ring, the substituted pyrrolo-pyridines can be present as cis-lac-tones (VI) or as trans-lactones (VII).
R2 _~

S R4~ cis-lactone........................ (VI) R2 ~
R5 ~ 1 A ~ o'~O trans-lactone (VII) R3 Rl In each case, two isomers, namely the 4R,6R-isomer or the 4S,6S-isomer (cis-lactone), and the 4R,6S-isomer or 4S,6R-isomer (trans-lactone) in turn exist both of the cis-lactone and the trans-lactone. Preferred isomers are the trans-lactones. ~he 4R,6S-isomer (trans) and the 4R,6S-4S,6R-racemate are particularly preferred in this case.

~he following isomeric forms of the substituted pyrrolo-pyridines may be mentioned as examples:

Le A 27 777 - 12 -20~734 R2 H~\~R6 R5~`~o~o R2 R6~0H

4 ~O~O

R2 ~R~

RS~O~O
R4~Nf ~R 1 R2 R6~0H

RS I I ~ J~o~o R4 ~N--~R 1 R5~--~CH-CH2-CR6-CH2-CooR7 R4~N~R 1 Le A 27 7?7 - 13 -209~6r~4 R5~--~f CH - CH 2 - CR6 - CH 2 - C ooR7 R4'--N~R 1 IRZ OH OH
R 5`11 -- ~CH - CH 2 - CR6 - CH 2 - C OOR7 R4 f ~N~N~R 1 RZ OH OH
RS~ ~ ~ CH - CH z - CR6 - CH z - t:~oOR7 R4~N~N~R 1 The substituted pyrrolo-pyridines of the general formula (I) are prepared by a proces6 in which ketones of the general formula (VIII) R2 o R5~ CH2-c-cH2-cooR9 (VIII ) R4 N~R 1 S in which Le A 27 777 - 14 -20~673~

Rl, R2, R3, R4 and R5 have the abo~ementioned meanings, R9 - represents alkyl, and E represents a group oR8 S -D-P- (VIIIa) or OH (VIIIb) -CH=CH-CH-are reduced, and in the case of the preparation of the acids, the esters are hydrolyzed, in the case of the preparation of the lactones, the carboxylic acids are cyclized, in the case of the preparation of the ethylene compounds (A = -CH2-CH2-), the ethenyl compounds (A - -CH=CH-) are hydrogenated by customary methods, and, if appropriate, isomers are separated.

Le A 27 777 - 15 -2 0 L~ 6 7 ~ 4 The process according to the invention can be illustrated by the following equation:

~CH2COOCH3 ~J~OH

H3C ¦ reduction F . .

~ ~CH2COOCH3 ;--~OH
~N~

hydrolysis ¢~ OH

~= OHCOOeNal3 Le A 27 777 - 16 -- 2~73~

I
.'- 1 cycliz~tion [~ OH
~COOH

~ = 0 The reduction can be carried out with the customary reducing agents, preferably with those which are suitable for the reduction of ketones to hydroxyl compounds. In this case, reduction with metal hydrides or complex metal hydrides in inert solvents, if appropriate in the pre-sence of a trialkylborane, is particularly suitable. The reduction is preferably carried out with complex metal hydrides such as, for example, lithium borohydride, sodium borohydride, potassi~m borohydride, zinc :

Le A 27 777 - 17 -- 2~6~3~

borohydride, lithium trialkylborohydrides, sodium tri-alkylborohydrides, sodium cyanoborohydride or lithium aluminum hydride. The reduction is very particularly preferably carried out with sodium borohydride in the presence of triethylborane.

Suitable solvents in this connection are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers such as, for example, diethyl ether, dioxane, tetrahydrofuran or dimethoxyethane, or halogenated hydrocarbons such as, for example, dichloromethane, trichloromethane, tetrachloro-methane, 1,2-dichloroethane, or hydrocarbons such as, for example, benzene, toluene or xylene. It is also possible to employ mixtures of the solvents mentioned.

If E represents the radical of the formula (~IIIa), alcohols such as methanol, ethanol or propanol, prefera-bly ethanol, are employed.

The reduction of the ketone group to the hydroxyl group is particularly preferably carried out under conditions in which the other functional groups such as, for example, the alkoxycarbonyl group, are not changed.

The use of sodium borohydride as the reducing agent is particularly suitable for this purpose, in the presence of triethylborane in inert solvents such as, preferably, ethers.

Le A 27 777 - 18 -2~73~

The reduction is in general carried out in a temperature range from -80C to +30C, preferably from -78C to 0C.

The process according to the invention is in general carried out at normal pressure. However, it is also possible to carry out the process at reduced pressure or at elevated pressure (for example in a range from 0.5 to S bar).

In general, the reducing agent is employed in an amount from 1 to 2 molS preferably from 1 to 1.5 mo~S relative to 1 mol of the keto compound.

~nder the abovementioned reaction conditions, the car-bonyl group is in general reduced to the hydroxyl group without reduction of the double bond to a single bond taking place.

In order to prepare compounds of the general formula (I) in which A represents an ethylene grouping, the reduction of the ketones (VIII) can be carried out under those conditions under which both the carbonyl group and the double bond are reduced.

Moreover, it is also possible to carry out the reduction of the carbonyl group and the reduction of the double bond in two separate steps.

The carboxylic acids in the context of the general formula (I) correspond to the formula (Ia) ~e A 27 777 - 19 -20~67~l~

4 ~ A - CH-CH2-C-CH2-COOH
R N ~ Rl OH OH
R3 ( Ia) in which Rl, R2, R3, R4, R5, R6 and A have the abovementioned mean-ings.

The carboxylic acid esters in the context of the general formula (I) correspond to the formula (Ib) R2 R6 '' R5 ~ A - CH-CH2-C-CH2-COOR9 (Ib) R4 ~ N ~ Rl OH OH

in which Rl, RZ, R3, R4, R5, R6 and A have the abovementioned mean-1 ingS

and R9 - represents alkyl.

The salts of the compounds according to the invention in the context of the qeneral formula (I) correspond to the formula (Ic) Le A 27 777 - 20 -20~673~

. .

R5~[$A---CH-CH2-C -CHz-COO- Mn~ ( Ic ) R4~'~N Rl OH OH . l in which - R3 n R1, RZ, R3, R4, R5, R~ and A have the abovementioned mean-ing~

and Mnt represents a cation.

The lactones in the context of the general formula (I) correspond to the formula (Id) HO~R
R2 ~ , R5~Alo~O
R4~N~R 1 (Id) in which R1, R2, R3, R4, R5, R6 and A have the abovementioned mean-ings.

In order to prepare the carboxylic acids of the general formula (Ia) according to the invention, the carboxylic Le A 27 777 - 21 -20~673~

.
- acid esters of the general formula (Ib) or the lactones of the general formula (Id) are in general hydrolyzed by customary methods. The hydrolysis is in general carried out by treating the esters or the lactones with customary bases in inert solvents, the salts of the general formula (Ic) in ~eneral being formed first, which can then be converted into the free acids of the general formula (Ia) in a second step by treatment with acid.

Suitable bases for the hydrolysis are the customaxy inorganic bases. These preferably include alkali metal hydroxides or alkaline earth metal hydroxides such as, for example, sodium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates such as sodium carbonate or potassium carbonate or sodium hydro-gen carbonate, or alkali metal alkoxides such as sodiumethoxide, sodium methoxide, potassium methoxide, potas-sium ethoxide or potassium tert-butoxide. Sodium hydroxi-de or potassium hydroxide are particularly preferably employed.

Suitable solvents for the hydrolysis are water or the organic solvents customary for hydrolysis. These prefer-ably include alcohols such as methanol, ethanol, pro-panol, isopropanol or butanol, or ethers such as tetra-hydrofuran or dioxane, or dimethylformamide or dimethyl sulphoxide. Alcohols such as methanol, ethanol, propanol or isopropanol are particularly preferably used. It is also possible to employ mixtures of the solvents men-tioned.

Le A 27 777 - 22 -20~673~
.

- The hydrolysis is in general carried out in a temperature range of O~C to +100C, preferably from +20C to +80C.

In general, the hydrolysis is carried out at normal pressure. However, it is also possible to work at reduced pressure or at elevated pressure (for example from 0.5 to 5 bar).

When carrying out the hydrolysis, the base is in general employed in an amount from 1 to 3 mob, preferably from 1 to 1.5 mo]s, relative to 1 mol of the ester or the lac-tone. Molar amounts of the reactants are particularlypreferably used.

When carrying out the reaction, the salts (Ic) of the compounds according to the invention are formed in the first step as intermediates which can be isolated. The acids (Ia) according to the invention are obtained by treating the salts (Ic) with customary inorganic acids.
These preferably include mineral acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid or phosphoric acid. In this connection, it has proved advantageous in the preparation of the carboxylic acids (Ia) to acidify the basic reaction mixture from the hydrolysis in a second step without isolating the salts.
The acids can then be isolated in a customary manner.

In order to prepare the lactones of the formula ~Id) according to the invention, the carboxylic acids (Ib) according to the invention are in general cyclized by Le A 27 777 - 23 -2~673~

.
customary methods, for example by heating the correspond-ing acid in inert organic solvents, if appropriate in the - presence of molecular sieve.

Suitable solvents in this connection are hydrocarbons such as benzene, toluene, xylene, mineral oil fractions, or tetralin or diglyme or triglyme. Benzene, toluene or xylene are preferably employed. It is also possible to employ mixtures of the solvents mentioned. Hydrocarbons are particularly preferably used, in particular toluene, in the presence of molecular sieve.

The cyclization is in general carried out in a tempera-ture range of -40C to ~200C, preferably from -25C to ~50 C

The cyclization is in general carried ou~ at normal pressure, but it is also possible to carry out the process at reduced pressure or at elevated pressure (for example in a range from 0.5 to 5 bar).

Moreover, the cyclization is also carried out in inert organic solvents, with the aid of cyclizing or dehydrat-ing agents. Carbodiimides are preferably used in thiscase as dehydrating agents. The preferred carbodiimides employed are N,N' dicyclohexylcarbodiimide, N-cyclohexyl-N'- E 2-(N"-methylmorpholinium)ethyl]carbodiimide para-toluenesulphonate or N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide hydrochloride.

Le A 27 777 - 24 -2~67~

Suitable solvents in this connection are the customary organic solvents. These preferably include ethers such as diethyl ether, tetrahydrofuran or dioxane, or chloro-hydrocarbons such as methylene chloride, chloroform or carbon tetrachloride, or hydrocarbons such as ben~ene, toluene, xylene or mineral oil fractions. Chlorohydro-carbons such as, for example, methylene chloride, chloro-form or carbon tetrachloride, or hydrocarbons such as benzene, toluene, xylene, or mineral oil fractions are particularly preferred. Chlorohydrocarbons such as, for example, methylene chloride, chloroform or carbon tetra-chloride are particularly preferably employed.

The reaction is in general carried out in a temperature range of from 0C to +80C, preferably from +10C to +50C.

When carrying out the cyclization, it has proved advan-tageous to employ the cyclization method using carbodi-imides as dehydrating agents.

The separation of the isomers into the stereoisomerically homogeneous constituents is in general carried out by customary methods such as are described, for example, by E.L. Eliel, Stereochemistry of Carbon Compounds, McGraw Hill, 1962. In this connection, the separation of the isomers from the racemic lactone stage is preferred. The racemic mixture of the trans-lactones (VII) is particu-larly preferably converted in this case by treating either with D-(+)- or L-(-)-~-methylbenzylamine by Le A 27 777 - 25 -2~6~3~

customary methods into the diastereomeric dihydroxyamides (Ie) R2 ~ ~ ~CH2-CONH-CH-C6H5 R5 ~ A H (Ie) R4 N ~ R1 R

which can then be ~eparated into the individual diaster-eomers by chromatography or crystallization, as is cu~to-mary. Subsequent hydrolysis of the pure diastereomeric amides by customary methods, for example by treating the diastereomeric amides with inorganic bases such as sodium hydroxide or potassium hydroxide in water and/or organic solvents such as alcohols, for example methanol, ethanol, propanol or isopropanol, gives the corresponding enantio-merically pure dihydroxy acids (Ia), which can be con-verted into the enantiomerically pure lactones by cycli-zation as described above. In general, it is true of the preparation of the compounds of the general formula (I) according to the invention in enantiomerically pure form that the configuration of the final products according to the method described above is dependent on the configura-tion of the starting materials.

The isomer ~eparation i~ illustrated by way of example in the following scheme:

Le A 27 777 - 26 -20~673'1 .

OH OH trans-racemate N

~ ~ H2N-CH-C6H5 CH2-co-NH-c*H-c6H5 ..
~` H
Nixture of diastereomers I ~ 1) Separation of diastereomers CH3 2) Hydrolysis 3) Lactonization S OH F OH
~ ~ ~0~0 Le A 27 777 - 27 -2~67~

- The ketones of the formula (VIIIa) employed as starting material~ are new and can be prepared in analogy to the process described in DE 3,817,298 A1.

The ketones (VIIIb) employed as starting materials are new.

A process for the preparation of the ketones of the general formula (VIIIb) according to the invention R2 o R5 ~ CH=CH-CH-CH2-~!-CH2-CooR9 ~VIII) R4~--~N--A~ ~ R1 OH

in which Rl, R2, R3, R4, R5 and R9 have the abovementioned meaning;

has been found, which is characterized in that aldehydes of the general formula (IX) R2 ~ H
R5~ __~ ~" (IX) R4J~N~R 1 Le A 27 777 - 28 -20~7~4 in which Rlr RZ, R3, R4 and R5 have the abovementioned meaning~

are reacted in inert solvents with acetoacetic acid esters of the general formula ~X) o 11 (X) H3C - C - CH2 - CooR9 in which R9 has the abovementioned meaning, in the presence of bases.

The process according to the invention can be illustr- ~
ated, for example, by the following equation:

~; ~ H3c-c-cH2-coocH3 CH3 ! ~a5e F o I~CH2COOCH3 I ~ OH

N~

Le A 27 777 - 29 -20~67~

- Suitable bases in this connection are the customary strongly basic compounds. These preferably include organolithium compounds such as, for example, n-butyl-lithium, sec-butyllithium, tert-butyllithium or phenyl-lithium, or amides, such as, for example, lithium diiso-propylamide, sodium amide or potassium amide, or lithium hexamethyldisilylamide, or alkali metal hydrides such as sodium hydride or potassium hydride. It is also possible to employ mixtures of the bases mentioned. N-Butyllithium or sodium hydride or a mixture thereof is particularly preferably employed.

Suitable solvents in this connection are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers such as diethyl ether, tetrahydrofuran, dioxane or dimethoxy-ethane, or hydrocarbons such as benzene, toluene, xylene, cyclohexane, hexane or mineral oil fractions. It is also possible to employ mixtures of the solvents mentioned.
Ethers such as diethyl ether or tetrahydrofuran are particularly preferably used.

The reaction is in general carried out in a temperature range from -80C to t50C, preferably from -20C to room temperature.

The process is in general carried out at normal pressure, but it is also possible to carry out the process at reduced pressure or at elevated pressure, for example in a range from 0.5 to 5 bar.

Le A 27 777 - 30 -2~73~

- When carrying out the process, the acetoacetic acid ester is in general employed in an amount from 1 to 2, prefer-ably from l to 1.5 mo~j relative to 1 mol of the alde-hyde.

The acetoacetic acid esters of the formula (X) employed as starting materials are known or can be prepared by known methods tBeilstein's Handbuch der organischen Chemie (Beilstein~s Handbook of Organic Chemistry) III, 632; 438].

Examples of acetoacetic acid ester~ which may be men-tioned for the process according to the invention are:
methyl acetoacetate, ethyl acetoacetate, propyl aceto-acetate or isopropyl acetoacetate.

The preparation of the aldehydes of the general formula (IX) employed as starting materials is illustrated by way of example as follows for the case in which X represents the group -A-B:

[A] 5 ~ COOR10 t1] Rs ~ CH2H
R4~`Nf~R 1 R4~NJ~R 1 R3 (XI ) R3 (XI I ~

R2 R2 H~CHO
t 2 ~ RS~CHO t 3~ R5~H
R4~N ~R1 R4~N~R
R3 (XIII) R3 (IX

Le A 27 777 - 31 -20~67~l~

.- In this connection, according to scheme A, pyrrolo-pyridines of the formula (XI), in which R10 represents alkyl having up to 4 carbon atoms, are reduced to the hydroxymethyl compounds (XII) in a first step tl] in inert solvents such as ethers, for example diethyl ether, tetrahydrofuran or dioxane, preferably tetrahydrofuran, using metal hydrides as reducing agents, for example lithium aluminNm hydride, sodium cyanoborohydride, sodium aluminum-hydride, diisobutylaluminum hyd,ide or sodium bis-(2-methoxyethoxy)-dihydroaluminate, in tem-perature ranges from -70-C to ~100C, preferably from -70C to room temperature, or from room temperature to 70C, depending on the reducing agent used. Reduction is prefera~ly carried out with diisobutylaluminum hydride or with lithium aluminum hydride in tetrahydrofuran in a temperature range from room temperature to 80C. The hydroxymethyl compounds (XII) are oxidiZed to the alde-hydes (XIII) by customary methods in a second step [2].
The oxidation can be carried out, for example, with pyridinium chlorochromate, optionally in the presence of alumina, in inert solvents such as chlorohydrocarbons, preferably methylene chloride, in a temperature range from 0C to 60C, preferably at room temperature, or else with trifluoroacetic anhydride/dimethyl sulphoxide by the customary methods of Swern oxidation. The aldehydes (XIII) are reacted to give the aldehydes (IX) in a third step [3] with diethyl 2-(cyclohexylamino)-vinylphosphon-ate in the presence of sodium hydride in inert solvents such as ether~, for example diethyl ether, tetrahydro-furan or dioxane, preferably in tetrahydrofuran, in a Le A 27 777 - 32 -20Ag73~

,- temperature range from -20C to +40C, preferably from -5C to room temperature.

The 2H-pyrrolo-pyridines (XI) employed as starting materials in this connection are in general obtained according to scheme tB] by first oxidizing the dihydro-pyridines of the formula XIV, in which R10 and R' are identical or different and have the abovementioned meaning, to the corresponding pyridines of the formula (XV), then first converting the ester function ~COOR~) into the corresponding hydroxymethyl compounds (XVI) by reduction and then oxidizing to the corresponding alde-hydes (XVII) and in a last step cyclizing by conventional methods:

~B] R10 o2c ~ COOR1O tl] R10 o2c ~ COOR1O
Il 11 . Il I
H 2M f ~N~R 1 H 2 N~R 1 (XIV) (XV) ~2] HO-H2C ~ CO2R1O r3] OHC ~ CO2R10 H2N~R 1 H2NJ~R 1 (XVI) R1 (XVII) [4] RS ~ CO2R10 R4J~N~R 1 (XI) Le A 27 777 _ 33 _ 2~7,'~

The dihydropyridines employed as starting ~aterials in this connection are new in some cases or known and can be prepared by known methods, for example by condensation of ethoxycarbonyl-acetamidine hydrochloride with (4-fluorophenyl)-2-methoxycarbonyl-4-methyl-pent-1-en 3-one tcompare additionally EP-A 88,276, DE-A 2,847,236].
The oxidation of the dihydropyridines (XIV) to give the pyrrolo-pyridines (XI) can be carried out, for example, with chromic oxide in glacial acetic acid in a tempera-ture range from -20 DC to ~150C, preferably at reflux temperature, or with 2,3-dichloro-5,6-dicyano-p-benzo-quinone as the oxidizing agent in inert solvents such as chlorohydrocarbons, preferably methylene chloride in a temperature range from 0C to +100C, preferably at room temperature.

The reduction to give the hydroxymethyl compounds of the formula (XVI) [step 2] is carried out using suitable reducing agents, such as, for example, lithium aluminum hydride, diisobutylaluminUm hydride or sodium bis-(2-methoxyethoxy)-dihydroaluminate in inert solvents, such as, for example, tetrahydrofuran.

The oxidation [step 3] to give the corresponding aldehydes (XVII) is carried out by the abovementioned method.

The cyclization tstep 4] is carried out by a Wittig reaction, if appropriate with sub~tituted (R`/R5 ~ H) phosphonium or pho~phorylidene, for example with methoxy-methyltriphenylphosphonium bromide, in the presence of a Le A 27 777 - 34 -2 ~ 3 ~ .

base in aprotic solvents, followed by hydrolysis in aqueous acid.
Suitable bases are alkali metal hydrides and amides, such as, for example, sodium amide or sodium hydride, or organic lithium compounds such as, for example, butyl-lithium or alkoxides such as potassium tert-butoxide.
Sodium amide is preferred.

Suitable solvents are the customary aprotic organic solvents such as, for example, tetrahydrofuran, dimethyl-formamide or dimethyl sulphoxide. Tetrahydrofuran ispreferred.

The base is employed in an amount of 1 to 4, preferably of 1 to 2 mol e~uivalents.

Acids employed in the hydrolysis are aqueous mineral acids, preferably half-concentrated hydrochloric acid.
The hydrolysis is carried out in a temperature range from 0 to 100C, preferably at 60 to 100C.

The compounds of the general formula (I) according to the invention have useful pharmacological properties and can be employed in medicaments. In particular, they are inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase and, as a result of this, inhibitors of cholesterol biosynthesis. ~hey can therefore be employed for the treatment of hyperlipoproteinaemia, lipoproteinaemia or arteriosclerosis. The active com-pounds according to the invention additionally cause a Le A 27 777 - 35 -2n~67~

..

lowering of the cholesterol content in the blood.

The enzyme activity determination was carried out as modified by G. C. Ness et al., Archives of Biochemistry and Biophysics 197, 493 - 499 (1979). Male Rico rats (body weight 300 - 400 g) were treated with altromin powdered feed, to which 40 g of colestyramine/kg of feed had been added, for 11 days. After decapitation, the livers were removed from the animals and placed on ice.
The livers were comminuted and homogenized 3 times in a Potter-Elve~em homogenizsr in 3 volumes of 0.1 M sucrose, O.05 M KCl, O.04 M R~ phosphate, 0.03 M ethylene-dia-minetetraacetic acid, 0.002 M dithiothreitol (SPE) buffer pH 7.2. The mixture was then centrifuged at 15,000 g for 15 minutes and the sediment was discarded. The super-natant was sedimented at 100,000 g for 75 minutes. The pellet was taken up in 1/4 volumes of SPE buffer, homo-geni~ed again and then centrifuged again at 100,000 g for 60 minutes. The pellet wa6taken up using a 5-fold amount of its volume of SPE buffer, homogeniæed and frozen and stored at -78C ~= enzyme solution).

For testing, the test compounds (or mevinolin as a reference substance) were dissolved in dimethylformamide with the addition of 5 vol. ~ of 1 N NaOH and employed in the enzyme test using 10 ~1 in various concentrations.
The test was begun after 20 minutes pre-incubation of the compounds with the enzyme at 37~C. The test mixture amounted to 0.380 ml and contained 4 ~mol of glucose ~-phosphate, 1.1 mg of bovine serum albumin, 2.1 ~mol of Le A 27 777 - 36 -~Q~673~

-.- dithiothreitol, 0.35 ~mol of NADP, 1 unit of glucose 6-phosphate dehydrogenase, 35 ~mol of X~ phosphate pH 7.2, 20 ~l of enzyme preparation and S6 nmol of 3-hydroxy-3-methyl-glutaryl coenzyme A (glutaryl-3-l~C) of 100,000 dpm.

After an incubation of 60 minutes at 37C, the mixture was centrifuged and 600 ~l of the supernatant was applied to a 0.7 x 4 cm column packed with a 5-chloride 100-200 mesh (snion exchanger). The column W~8 washed with 2 ml of distilled water and 3 ml of Aquasol was added to the runnings plus washing water and counted in an LRB scin-tillation counter. IC50 values were determined by intra-polation by plotting the percentage inhibition against the concentration of the compound in the test. In order to determine the relative inhibitory potency, the IC50 value of the reference ~ubstance mevinolin was set at 1 and compared with the simultaneously determined ICsOvalue of the test compound.

Exar,ple No. in~o relative activity Me~nolin=l _ la 3 2a 3 lb 3 2b 3 lc 13 2c 3 Ig 4 .
2g 2 If 17 2f 10 li 9 lh 33 2h 10 le 17 Id 27 1j 24 Le A 27 777 - 37 _ .. .. ... . . . .. . " .

2 0 ~

The present invention nlfio includeg pharmaceutical ~0 preparations which, in addition to inert, non-toxic, pharmaceutical auxiliarieg and excipients, contain one or more compounds of the general formula (I), or which consist of one or more active compounds of the formula (I), and processes for the production of these preparations.

The active compounds of the formula (I) should be present in these preparation~ in a concentration of 0.1 to 99.5~
. by weight, preferably of 0.5 to 95% by weight of the total mi~ture.

In addition to the active compounds of the formula (I), the pharmaceutical preparations can also contain other pharmaceutical ly active compounds.

The abovementioned pharmaceutical preparations can be prepared by known methods in a customary manner, for example using the auxiliary or auxiliaries or excipient(s).

In generall it has proved advantageous to administer the active compound(s) of the for;mula (I) in total amounts of about 0.0005 to about 20 mg/kg, preferably in total amounts of about 0.001 mg/kg to S mg/kg of body weight every 24 hours, if desired in the form of several lS individual doses, to achieve the desired results.

However, it may be advantageous to deviate from the amounts mentioned, in part$cular depending on the specieQ
and body weight of the sub~ect to be treated, on indiv1-dual behaviolr towards the medicament, the nature and severity of the diqease, the type of preparation and administration, and the time or interval at which admin-istration takes place.

Le A 27 777 - 38 -. .

2~67~'~

Startin~ compounds Example ~

(E)-Z-1-(4-Fluorophenyl)-2-methoxycarbonyl-4-methyl-pent-l-en-3-one ~COOCH3 ~C-CH-CH3 A solution of 22.5 ml (0.223 mol) of piperidine and 13.5 ml (0.23 mol) of acetic acid in 100 ml of iso-propanol is added to 576.7 g (4 mol) of methyl isobu-tyryl-acetate and 496.5 g (4 mol) of 4-fluorobenzaldehyde in 1 1 of isopropanol. The mixture is stirred at room temperature for 1 day and concentrated in vacuo, and the residue is distilled in a high vacuum.
Yield: 840.7 g (84~ of theory) of yellowish oil B.p.: 150-152-C ~4 mbar) ExamEle II

2-Amino-3-ethoxycarbonyl-4-(4-fluorophenyl)-6-isopropyl-5-methoxycarbonyl-1,4-dihydropyrldine Le A 27 ?77 - 39 -20~6734 ~3 H3C-~2C-OOC ~ ~CH3 H~NA~N H
H ~CH3 66.6 g tO.4 mol) of ethyl 3,3-diaminoacrylate hydro-chloride and 100 g (0.4 mol) of the compound from Example l are heated to reflux overnight with 44 ml (0.4 mol) of N-methylmorpholine in sao ml of isopropanol.
The mixture is concentrated in vacuo and the residue is chromatographed in a column (~ 20 cm) on 2 ~g of silica gel 230-400 mesh using petroleum ether~ethyl acetate (2:1).
Yield: 109.7 g (75.7% of theory) of colorless crystals M.p.: 161C (from ether/petroleum ether) Example III

2-Amino-3-ethoxycarbonyl-4-(4-fluorophenyl)-6-isopropyl-5-methoxycarbonyl-pyridine F

H3c-H2c-ooc~coocH3 H2N~

Le A 27 777 - 40 -. . ~ . . , 2~ 73l~

22.7 g (0.1 mol) of 2,3-dichloro-4,5-dicyano-benzoquinone are added to a solution of 36.2 g (0.1 mol) of the compound from Example II in 2 1 of dichloromethane and the mixture is stirred at room temperature for 40 min.
S The suspension is filtered through 1.5 kg of silica gel 230-400 mesh in a glass suction filter and eluted using a mixture of petroleum ether/ethyl acetate 2:1. The eluate is concentrated in vacuo and the residue which remains is thoroughly stirred in ether/petroleum ether and filtered off with suction.
Yield: 31.6 g (88% of theory) M.p.: 141C

Example IV

2-Amino-4-(4-fluorophenyl)-3-hydroxymethyl-6-isopropyl-5-methoxycarbonyl-pyridine HO-HzC~_~_~COOCH3 H2NJS~

100 ml (0.35 mol) of a 3.5 M solution of sodium bis-(2-methoxy-ethoxy)-dihydroaluminate in toluene are initially introduced under argon into 100 ml of tetra-hydrofuran p.a. 63 g (175 mmol) of the compound from Le A 27 777 - 41 -2n~rl3~

.- Example III dissolved in 700 ml of tetrahydrofuran are added dropwise and the mixture is subsequently stirred at - 30C for 1 h. 2 1 of water are cautiously added dropwise.
The phases are separated and the aqueous phase is washed twice with 700 ml of ethyl acetate. The combined organic phases are washed with 500 ml of saturated sodium chloride solution and dried using sodium sulphate. The solution is filtered and concentrated in vacuo. The residue is chromatographed in a column (~ 6 cm) on 400 g of silica gel 230-400 mesh using petroleum ether~ethyl acetate (1:1). The eluate is concentrated in vacuo and the residue is thoroughly stirred in ether/petroleum ether.
Yield: 45.2 g (81.2~ of theory) of colorless crystals M.p.: 137C

Example V

2-Amino-4-(4-fluorophenyl)-3-formyl-S-methoxycarbonyl-6-isopropyl-pyridine OHC ~ COOCH3 H2N~

20.7 g (65 mmol) of the compound from Example IV are dissolved in 1.5 1 of dichloromethane, 13.3 g (0.13 mol) Le A 27 777 - 42 -2~6 ~4 . of neutral alumina and 28 g (0.13 mol~ of pyridinium chlorochromate are added and the mixture is stirred at ~ room temperature for 1 hour.

The suspension is filtered through l kg of silica gel S 230-400 mesh in a glass suction filter, eluted without sucking dry using petroleum ether/ethyl acetate 3:1 and the eluate is concentrated to dryness in vacuo.
Yield: 13.4 g (65~ of theory) M.p.: 152C

Exa~ le VI

4-(4-Fluorophenyl)-6-isopropyl-5-methoxycarbonyl-lH-pyrrolo(2,3-b)pyridine F

~3 ~OCH~

23.9 g (55 mmol) of a mixture of methoxymethyltriphenyl-15phosphonium bromide and sodium amide are covered with a layer of 145 ml of anhydrous tetrahydrofuran and the mixture is stirred vigorously for 15 min. 17.4 g (55 mmol) of the compound from Example V are added to 145 ml of tetrahydrofuran and the mixture is stirred at 20room temperature for l h. A further 23.9 g (55 mmol) of Le A 27 777 - 43 -. ~ . . . . . .. .. . .

2~fi~3~

.- methoxymethyltriphenylphosphonium bromide/sodium amide are added and the mixture is stirred at room temperature for 60 min. 185 ml (1.11 mol) of 6 M hydrochloric acid are added, and the mixture is heated to reflux for 1 h and cooled. ~t is neutralized using 5 M sodium hydroxide solution and the phases are separated. The aqueous phase is extracted twice with ethyl acetate, and the combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulphate and concentrated to dryness. The residue which remains is dissolved in dichloromethane and added to a glass frit (porosity 3) which contains 4S0 g of silica gel 230-400 mesh. The mixture is eluted without sucking dry using a gradient of petroleum ether/ethyl acetate of 4:1 to 2:1. The eluate is concentrated to dryness in vacuo and the residue is thoroughly stirred in a mixture of ether/petroleum ether.
Yield: 13.8 g (80% of theory) of colorless crystals M.p.: 187C

Exam~le VII

4-(4-Fluorophenyl)-S-hydroxymethyl-6-isopropyl-lH-pyr-rolo(2,3-b)pyridine ~2-OH

Le A 27 777 - 44 -2~6~

100 ml of a 1.5 M solution of diisobutylaluminum hydride in toluene are added slowly at -78C under argon to a suspension of 15.6 g (50 mmol) of the compound from Example VI in 700 ml of toluene, which leads to a clear solution. After 1 h, 40 ml of 1.5 M diisobutylaluminum hydride solution are added at the same temperature and the mixture is stirred for a further hour. It is warmed to 0 - 5C using a water bath and stirred at this temper-ature for 1 h. 150 ml of water and 100 ml of ethyl acetate are cautiously added, and the mixture is stirred at room temperature for 1 h and filtered off with suction using kieselguhr. The phases are separated, the aqueous phase is extracted with ethyl acetate and the combined organic phases are washed with saturated sodium chloride solution. The solution is dried over sodium sulphate, concentrated to dryness in vacuo and the residue which remains is thoroughly stirred in dichloromethane.
Yield: 3.7 g The kieselguhr residue is extracted by boiling twice with ethyl acetate and filtered off with suction. The filtrat-es are combined, washed with saturated sodium chloride solution, dried over sodium sulphate, concentrated in vacuo and the residue is stirred thoroughly in dichloro-methane.
Yield 8.3 g Total yield: 12.0 g (84% of theory) of colourless crystals M.p.: 230C

Le A 27 777 - 45 -20~673A

Example VIII

4-(4-Fluorophenyl)-5-formyl-6-isopropyl-lH-pyrrolo-[2,3-b]pyridine F

~o 23.9 g (84 mmol) of the compound from Example V~I are suspended in 1.6 1 of dichloromethane, 17.1 g of neutral alumina and 36.1 g (168 mmol) of pyridinium chloro-chromate are added and the mixture is stirred at room temperature for 1 h. The suspension is filtered through 1.2 kg of silica gel (230-400 mesh) in a glass suction filter and washed without sucking dry using petroleum ether/ethyl acetate 3:2. The eluate is concentrated to dryness in vacuo and the residue which remains is stirred thoroughly in ether.
Yield: 15.4 q (65% of theory) of colorless crystals ~.p. 190C

Example IX-a (E)-3-t4-(4-Fluorophenyl)-6-isopropyl-lH-pyrrolo~2,3-b]-pyridin-5-yl]prop-2-enal Le A 27 777 - 46 -20~673~

~3 ~CHO

A solution of 11 g (42 mmol) of diethyl 2-(cyclohexyl-amino)-vinyl-phosphonate in 60 ml of tetrahydrofuran are added dropwise under argon in the course of 10 min to a suspension of 2.52 g (84 mmol) of 80% strength sodium hydride in 60 ml of anhydrous tetrahydrofuran. 9.9 g (35 mmol) of the compound from Example VIII dissolved in 100 ml of tetrahydrofuran are added dropwise at reflux.
The mixture is allowed to boil under reflux for 90 min and is cooled, treated with water and extracted several times with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution and concentrated in vacuo. The residue is dissolved in 300 ml of toluene and heated under reflux for 1 h with 22.9 g (182 mmol) of oxalic acid dihydrate in 350 ml of water.
The mixture is cooled, the phases are separated and the aqueous phase is extracted twice with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulphate and con-centrated to dryness in vacuo. The residue i9 dissolved in dichloromethane and filtered through 400 g of silica gel 230-400 mesh in a glass suction filter. The mixture Le A 27 777 - 47 -20~673~

is eluted without sucking dry using petroleum ether/ethyl acetate 1:1, the eluate is concentrated in vacuo and the residue is stirred thoroughly in ether.
Yield: 9.2 g (85% of theory) of colo~less crystals M.p.: 236C

Example IX-b (E)-3-~4-(4-Fluorophenyl)-6-isopropyl-1-methyl-lH-pyrrolot2,3-b]pyridin-5-yl]prop-2-enal F

~J ~CHO

N~

2 g (6.55 mmol) of the compound from Example IX-a are dissolved in 40 ml of anhydrous dimethylformamide and 0.8 g (7.15 mmol) of potassium tert-butoxide is added.
The mixture is stirred at room temperature for 15 min, 1.02 g (7.15 mmol) of methyl iodide are added and the mixture is stirred for a further 60 min at room tempera-ture. It is poured into 150 ml of water, extracted several times with ethyl acetate, and the combined organic phases are washed with saturated sodium chloride solution, dried using sodium sulphate and concentrated to dryness in vacuo. The residue which remains is chromato-Le A 27 777 - 48 -2~4~

graphed in a column (~ 4 cm) on 100 g of silica qel 230-400 mesh using petroleum ether/ethyl acetate 5:1. The eluate is concentrated in vacuo and stirred thoroughly in ether/petroleum ether.
S Yield: 1.15 g (54~ of theory) of colo~less crystals M.p.: 125C

The compounds shown in Table 1 were prepared in analogy to Example IX-b:

Le A 27 777 - 49 -2~6~3~

C~ U
O. ~ o ,,~ o x ~s x s~
n ~ , U~ U ', ..
oO ~ o o ~ Z~
~ ,. "
.~ ~ .. ..
U O
.C ,C '- N
N _ _ _ O _ ~c~z, qccc~?

U L ~S C
U a~
~zu~u ?
U N N U
~ ~ Y s ~r ~
~U~ U U N
I , , :1:
U, U 'O ~ '--X X X X X
cl E~

Le A 27 7?7 3 ~ ~ ~

o U~ .,, o~ ~ ~P. o a:~ O
.
a~
W
a) ~ o C~ a~ H J
~ ~ ~ ~ t` Ul W ~ ~
~ O ~ ~

~ u a) U~
~ ~ ~ S
O ~ `
~ ~ O a~
U ~ ~ U 15"1 H
- ~ X X ~ X
_ , x .q a~ L L X N W ~ U
a~ S
''I .C
U~ ~ O (~
~ U~
u ~a l; ~ h O ~ O ~ O
~.1 Q ~ ~ ~
~; ,~ N ,~ Z
X ~ ~S O
, N N N N
~0 .,, ~J ~ a o 1~ h a~ ~1 ~ . .,~ ~ O u~ ~ e e o h tr w .,1 .. 1 o Z ~ O 3 ~ O
~ . ~ 1 W ~ ~ S"~
O X x x x x ~ o c~ , ~
_I
a E~ X XX
Le A 27 777 - 51 -20~67~

~ PreParation Examples (general formula I) _ample la Methyl erythro-(E)-7-~4-(4-fluorophenyl)-6-isopropyl-lH-pyrrolo~2~3-b]pyridin-s-yl]3ts-dihydroxy-hept-6-enoate ~ ~ ~ COOCH3 H ~

0.61 g (5.25 mmol) of methyl acetoacetate is added dropwise at 0-5C to a suspension of 0.32 g (10.5 mmol) of 80% strength sodium hydride in 10 ml of anhydrous tetrahydrofuran. After 15 min, 6.6 ml (10.85 mmol) of 15% strength butyllithium in hexane are added dropwise in the course of 10 min and the mixture is kept at 0-5C for a further 15 min. 1.1 g (3.5 mmol) of the compound from Example IX-a in 10 ml of tetrahydrofuran are added to this mixture and it is stirred at room temperature for lS 45 min. It is then treated cautiously with 1.35 g (22.4 mmol) of acetic acid in 25 ml of water, extracted twice with ethyl acetate, and the combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulphate and concentrated in vacuo. The Le A 27 777 - 52 -2~3~73~

. residue which remains is dissolved in 20 ml of tetra-hydrofuran. 4.2 ml ~4.2 mmol) of a 1 M triethylborane solution in tetrahydrofuran is added and air is blown through the solution for 5 min. 0.16 g (4.2 mmol) of sodium borohydride are added at -78C. 3.5 ml of methanol are then added dropwise and the mixture is kept at -78C
to -75C for 1 h. It is then allowed to warm to room temperature, 11.6 ml of 30~ strength hydrogen peroxide and 30 ml of water being added from -30C. The mixture is extracted twice with ethyl acetate, and the combined organic phases are washed with saturated sodium chloride solution, dried over sodium sulphate and concentrated in vacuo. The residue which remains is chromatographed in a column ~ 3 cm) on 40 g of silica gel 230-400 mesh using petroleum ether/ethyl acetate 1:1. The eluate i9 con-centrated in vacuo and stirred thoroughly in ether.
Yield: 0.65 (43~ of theory) M.p.: 163C

In analogy to Example I-a, the p~ducts shown in Table 2 are obtained from 7 mmol of sodium hydride, 5.25 mmol of ethyl acetate, 10.85 mmol of butyllithium and 3.5 mmol of the respective compound from Example IX-b-;, the mixture being worked up using 19 mmol of acetic acid.

Le A 27 777 - 53 -2~73~

Table 2 F
OH OH

~J 1,~COOCH3 R
Ex. R Prepared fromYield M.p.
No. Example (%) (C) ;, l-b '-CH3 IX-b 42 74 l-c -CH(CH3)2 IX-c 38 101 l-d -CH2-CN IX-d 3 amorph.
l-e -CH2-C-CH IX-e 13 88 1 f CH2 CH2 ~ IX-f 49 124 1-9 -CH2 ~ IX-g 42 126 l-h -cH2-cH=cH2 IX-h 37 104 l-i-CH2 ~ IX-i 25 oil l-j-CH2-CHz-CN IX-j 18% oil Le A 27 777 - 54 -. ..

.

2~73~

Example 2-a Sodium erythro-(E)-7-[4-(4-fluorophenyl)-6-isopropyl-lH-pyrrolot2,3-b]pyridin-5-yl]-3,5-dihydroxy-hept-6-en-oate OH OH
~COO Na . ~ ..

3.3 ml (0.33 mmol~ of 0.1 M sodium hydroxide solution are added to a solution of 141 mg (0.33 mmol) of the compound from Example I-a in 3.3 ml of tetrahydrofuran and the mixture is stirred at room temperature for 1 h, concen-trated to dryness in vacuo and dried over phosphoruspentoxide in a high vacuum.
Yield: 120 mg (83% of theory) M.p.: 243C (dec.) The compounds given in Table 3 were prepared in analogy to the procedure of Example 2-a:

Le A 27 777 - 55 -20~7~'1 .

. ~ Table 3 F

~ ~C2 Na Ex . No . R Yield M . p . Starting (96 of theory) (C) compound 2-b -CH3 94 23l l-b ( dec . ) 2-c ~ 49 221 l-c ( dec . ) 2-f ~ (CH2)2~> 91 234 l-f 2-9 -CH2~3 99 (dec. ) 1-9 2-h -CH2-CH=CH2 89 234 l-h ( dec . ) Le A 27 777 - 56 -2~7~l~

Example 3-b F

[~J ~COOCH

~N

176 mg (0.4 mol) of the compound from Example 2 are dissolved in 30 ml of methanol and 20 ~1 of triethylamine and the solution is hydrogenated for 4.S h at normal pressure and room temperature using 150 mg of 10 strength palladium/carbon. The catalyst is filtered off, the solution is concentrated to dryness and the residue is partitioned between ethyl acetate and saturated sodium chloride solution. The organic phase is dried, concen-trated and crystallized from ether/petroleum ether.
Yield: 91 mg (51~ of theory) of colorless crystals M.p.: 97C

It will be understood that the specification and examples are illustrative but not limitative of the :presentinvention and that other embodiments within the spiritand scope of the invention will suggest them-selves to those skilled in the art.

Le A 27 777 - 57 -

Claims (19)

1. A substituted pyrrolo-pyridine of the formula (I) in which R1- represents straight-chain or branched alkyl having up to 8 carbon atoms, or - represents cycloalkyl having 3 to 6 carbon atoms, R2- represents phenyl which is optionally monosub-stituted or disubstituted by indentical or different substituents from the group consisting of straight-chain or branched alkyl having up to 6 carbon atoms, trifluoromethyl, hydroxymethyl, phenoxy, benzyl, benzyloxy and halogen, R3- represents hydrogen, - represents straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally sub-stituted by cyano, straight-chain or branched alkoxy having up to 6 carbon atoms, halogen, pyridyl, quinolinyl, furyl, thienyl, naphthyl or phenyl, each of which can in turn be substituted by halogen, Le A 27 777 - 58 -cyano, nitro, or straight-chain or branched alkyl or alkoxy in each case having up to 6 carbon atoms, - represents straight-chain or branched alkenyl or alkynyl in each case having up to 8 carbon atoms, or - represents cycloalkyl having 3 to 6 carbon atoms or phenyl, R4 and R5 are identical or different and - represent hydrogen, or - represent straight-chain or branched alkyl having up to 6 carbon atoms, which is optional-ly substituted by hydroxyl, halogen, cyano or alkoxy having up to 4 carbon atoms, X - represents a radical of the formula -A-B, in which A - denotes a group of the formula -CH2-CH2- or -CH=CH-, B - denotes a group of the formula or in which Le A 27 777 R6 _ denotes hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms and R7 - denotes hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which can be substituted by phenyl, or - denotes aryl having 6 to 10 carbon atoms or a cation, or - represents a radical of the formula in which D - denotes a radical of the formula -(CH2)t, -CH=CH-, -C=C- or -CH2-O-, in which the latter is bonded to the phosphorus atom via O, Le A 27 777 R8- denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, and t - denotes the number 1 or 2, or a salt thereof.
2. A substituted pyrrolo-pyridine according to Claim 1, in which R1 - represents straight-chain or branched alkyl having up to 6 carbon atoms, or - represents cyclopropyl, cyclopentyl or cyclo-hexyl, R2 _ represents phenyl which is optionally sub-stituted by straight-chain or branched alkyl having up to 4 carbon atoms, trifluoromethyl, fluorine, chlorine or bromine, R3 - represents hydrogen, - represents straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally sub-stituted by cyano, straight-chain or branched alkoxy having up to 4 carbon atoms, fluorine, chlorine, bromine, pyridyl or phenyl, each of which can in turn be substituted by fluorine, chlorine, bromine cyano, nitro, straight-chain or branched alkyl or Le A 27 777 alkoxy in each case having up to 4 carbon atoms, - represents straight-chain or branched alkenyl or alkynyl in each case having up to 6 carbon atoms, - represents cyclopropyl, cyclopentyl, cyclohexyl or phenyl, R4 and R5 represent hydrogen, X - represents a radical of the formula -A-B, in which A - denotes a group of the formula -CH2-CH2- or -CH=CH-, B - denotes a group of the formula or in which R6 - denotes hydrogen and R7 - denotes hydrogen or straight-chain or branched alkyl having up to 8 carbon atoms Le A 27 777 or benzyl, or - denotes phenyl or a cation, or a salt thereof.
3. A substituted pyrrolo-pyridine.
according to Claim 1, in which R1- represents straight-chain or branched alkyl having up to 4 carbon atoms or cyclopropyl, R2- represents phenyl which is optionally substituted by methyl, trifluoromethyl, fluorine or chlorine, R3- represents hydrogen, - represents straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by cyano, methoxy, fluorine, pyridyl or phenyl, - represents straight-chain or branched alkenyl or alkynyl in each case having up to 4 carbon atoms, or - represents cyclopentyl or cyclohexyl, R4 and R5 represent hydrogen, X - represents a radical of the formula -A-B, in which Le A 27 777 A - denotes a group of the formula -CH2-CH2- or -CH=CH-, B - denotes a group of the formula or in which R6 _ denotes hydrogen and R7 - denotes hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or benzyl, or - denotes a sodium, potassium, calcium, magnesium or ammonium ion, or a salt thereof.

Le A 27 777 - 64 -
4. Methyl 7-[1-allyl-4-(4-fluorophenyl)-6-isopropyl-1H-pyrrolo(2,3-b)pyridin-5-yl]3,5-dihydroxy-hept-6-enoate of the formula
5. Methyl 7-[1-(2-cyanoethyl)-4-(4-fluorophenyl)-6-isopropyl-1H-pyrrolo(2,3-b)pyridin-5-yl]3,5-dihydroxy-hept-6-enoate of the formula
6. Methyl 7-[1-cyanomethyl-4-(4-fluorophenyl)-6-isopropyl-1H-pyrrolo(2,3-b)pyridin-5-yl]3,5-dihydroxy-hept-6-enoate of the formula
7. 7-[4-(4-Fluorophenyl)-1,6-diisopropyl-pyrrolo(2,3-b) pyridin-5-yl]-3,5-dihydroxy-hept-6-enoic acid of the formula or a salt thereof.
8. 7-[4-(4-Fluorophenyl)-6-isopropyl-(1-phenethyl)-pyrrolo(2,3-b)pyridin-5-yl]-3,5-dihydroxy-hept-6-enoic acid of the formula or a salt thereof.
9. 7-[1-Allyl-4-(4-fluorophenyl)-6-isopropyl-pyrrolo (2,3-b)pyridin-5-yl]-3,5-dihydroxy-hept-6-en-1-oic acid of the formula ar a salt thereof.
10. Sodium 7-[4-(4-fluorophenyl)-1,6-diisopropyl-pyrrolo(2,3-b)pyridin-5-yl]-3,5-dihydroxy-hept-6-enoate.
11. Sodium 7-[4-(4-fluorophenyl) -6-isopropyl- (1-phenethyl)-pyrrolo(2,3-b)pyridin-5-yl]-3,5-dihydroxy-hept-6-enoate.
12. Sodium 7-[1-allyl-4-(4-fluorophenyl)-6-isopropyl-pyrrolo(2,3-b)pyridin-5-yl]-3,5-dihydroxy-hept-6-enoate.
13. A compound according to any one of claims 1 to 3 or 7 to 9 wherein the salt is a pharmaceutically acceptable salt.
14. A composition for treating hyperlipoproteinaemia, lipoproteinaemia or arteriosclerosis comprising an amount effective therefor of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 together with a pharmaceutically acceptable diluent or carrier.
15. A process for preparing a compound according to claim 1 wherein R1, R2, R3, R4, R5 and X are as defined in claim 1, which comprises reducing a ketone of the formula VIII

(VIII) in which R1, R2, R3, R4 and R5 have the abovementioned meanings, R9 - represents alkyl, and E represents a group (VIIIa) or (VIIIb) and where required hydrolyzing an ester to obtain an acid or cycli-zing a carboxylic acid to obtain a lactone or hydrogenating an ethenyl compound to obtain an ethylene compound, and where required forming a salt thereof.
16. A use for treating hyperlipoproteinaemia, lipoprotein-aemia or arteriosclerosis in a patient suffering therefrom of an amount effective therefor of a compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12.
17. A commercial package comprising a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12 as an active ingredient together with instructions for the use thereof for the treatment of hyperlipoproteinaemia, lipoproteinaemia or arteriosclerosis.
18. A compound of the formula VIIIb (VIIIb) wherein R1, R2, R3, R4 and R5 are as defined in claim 1 and R9 is alkyl.
19. A process for preparing a compound of the formula VIIIb as defined in claim 18, wherein R1, R2, R3, R4, R5 and R9 are as defined in claim 18, which process comprises reacting an aldehyde of the general formula IX

(IX) in which R1, R2, R3, R4 and R have the abovementioned meanings, in an inert solvent with an acetoacetic acid ester of the general formula X

(X) in which R9 has the abovementioned meaning, in contact with a base.
CA002046734A 1990-07-13 1991-07-10 Substituted pyrrolo-pyridines pharmaceuticals Abandoned CA2046734A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022414A DE4022414A1 (en) 1990-07-13 1990-07-13 SUBSTITUTED PYRROLO-PYRIDINE
DEP4022414.7 1990-07-13

Publications (1)

Publication Number Publication Date
CA2046734A1 true CA2046734A1 (en) 1992-01-14

Family

ID=6410265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002046734A Abandoned CA2046734A1 (en) 1990-07-13 1991-07-10 Substituted pyrrolo-pyridines pharmaceuticals

Country Status (5)

Country Link
US (1) US5120782A (en)
EP (1) EP0465970A1 (en)
JP (1) JPH04230381A (en)
CA (1) CA2046734A1 (en)
DE (1) DE4022414A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687402B1 (en) * 1992-02-14 1995-06-30 Lipha NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
DE4243279A1 (en) * 1992-12-21 1994-06-23 Bayer Ag Substituted triplets
US5451566A (en) * 1993-11-17 1995-09-19 Zeneca Limited Herbicidal pyrrolopyridine compounds
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
PL1696920T3 (en) 2003-12-19 2015-03-31 Plexxikon Inc Compounds and methods for development of ret modulators
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
NZ563444A (en) * 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
DK1893612T3 (en) * 2005-06-22 2011-11-21 Plexxikon Inc Pyrrole [2,3-B] pyridine derivatives as protein kinase inhibitors
CA2635899A1 (en) * 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
EP2094701A2 (en) 2006-12-21 2009-09-02 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20121126A1 (en) * 2006-12-21 2012-08-24 Plexxikon Inc PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX349923B (en) * 2009-04-03 2017-08-21 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof.
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
JP2013510166A (en) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド Compounds, methods and applications for kinase regulation
PL2672967T3 (en) 2011-02-07 2019-04-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (en) 2011-02-21 2013-09-18 Plexxikon Inc SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN103058996B (en) * 2012-12-21 2017-03-22 北京华禧联合科技发展有限公司 Nitrogen heterocyclic compound preparation method and application thereof
CN111225672B (en) 2017-10-16 2023-09-29 清华大学 Mevalonate pathway inhibitor and pharmaceutical composition thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) * 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
DE3911064A1 (en) * 1989-04-06 1990-10-11 Bayer Ag SUBSTITUTED 1,8-NAPHTHYRIDINE
US5025000A (en) * 1990-03-02 1991-06-18 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitor compounds

Also Published As

Publication number Publication date
EP0465970A1 (en) 1992-01-15
JPH04230381A (en) 1992-08-19
DE4022414A1 (en) 1992-01-16
US5120782A (en) 1992-06-09

Similar Documents

Publication Publication Date Title
CA2046734A1 (en) Substituted pyrrolo-pyridines pharmaceuticals
US5006530A (en) Certain 7-[2,6-diisopropyl-4-phenyl-5-lower alkoxymethyl-pyrid-3-yl]-3,5-dihydroxy-6-enoates and derivatives useful for treating circulatory diseases
US5401746A (en) Substituted pyridines heptenoic acid derivatives, useful for treating arterioscleros, lipopotaemia and the like
JP2954954B2 (en) Substituted 2-pyridones and pyrid-2-thiones, processes for their preparation, and their use in medicine
US4992462A (en) Substituted pyrroles
JP2712107B2 (en) Disubstituted pyridines
EP0312269B1 (en) 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
US5034399A (en) Substituted 1,8-naphthyridines and their use in medicaments
US5075311A (en) Hmg-coa reductase inhibiting substituted pryido (2,3-d) pyrimidines
US4829081A (en) Analogs of mevalonolactone and derivatives thereof
US5137881A (en) Substituted pyrido-oxazine inhibitors of hmg-coa reductase
NO890521L (en) SUBSTITUTED PYRIMIDINES.
US5145959A (en) Substituted pyrido (2,3-d) pyrimidines as intermediates
US5138090A (en) Substituted biphenyls
US5164506A (en) Substituted 2-pyridones and pyrid-2-thiones compounds
US4937255A (en) Disubstituted pyrroles
IE902802A1 (en) Imino-substituted pyridines
US4973598A (en) Substituted imidazolinones and imidazolinethiones
IE903231A1 (en) Substituted amino-pyridines
US4495354A (en) Process for bicyclic diketones
AU630390B2 (en) Substituted 2-pyridones and pyrid-2-thiones, processes for their preparation and their use in medicaments
US4812583A (en) Substituted acyloxyalkylphenylethylene inhibitors of 3-hydroxy-3-methylglutaryl-coa reductase
US5470982A (en) Disubstituted pyridines
US5173495A (en) 7-[(2,6-dialkyl-4-furyl or thienyl-pyridyl)]-3,5-di-(dihydroxy-6-enoates) useful for treating circulatory diseases

Legal Events

Date Code Title Description
FZDE Dead